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Abstract 
Heterogeneous nuclear ribonucleoprotein 
(HNRNPA1) gene maps to chromosome 12, plus 
strand and has 13 exons and 12 introns. There are 
three reported transcripts due to the alternative 
splicing.  
HNRNPA1 is one of the most abundant and 
ubiquitously expressed nuclear proteins. HNRNPA1 
is a member of RNA-binding protein family 
comprising of 20 members in humans (Dreyfuss, 
1993; Pinol-Roma, Choi, Matunis,  Dreyfuss, 1988). 
HNRNPA1 has diverse roles in RNA splicing, 
telomere length maintenance, miRNA maturation 
and mRNA transport from nucleus to cytoplasm. 
Keywords 
HNRNPA1; RNA-binding protein; RNA splicing; 
telomere length maintenance; miRNA maturation; 
mRNA transport 
Identity 
Other names: HNRPA1, ALS20, hnRNP A1, 
hnRNP-A1, IBMPFD3, UP 1, HNRPA1L3 
HGNC (Hugo): HNRNPA1 
Location: 12q13.13 
Local order 
From telomere to centromere: LOC105369777, 
CBX5, ENSG00000257596, HNRNPA1, NFE2, 
ENSG00000258344, COPZ1, GPR84 
DNA/RNA 
Note 
HNRNPA1 gene consists of 13 exons and 12 introns. 
The gene maps to 12q13.13 and is 6399 bps long 
(NCBI Reference Sequence: NC_000012.12: 
54280690-54287088). Highlighted in red is the 
protein coding sequence from exons 1-10. (Figure 2) 
Local order of HNRNPA1 together with neighboring upstream and downstream genes on chromosome 12. The direction of 
arrows indicates direction of transcription and arrow sizes approximate gene sizes. 
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HNRNPA1 gene has 13 exons and 12 introns. Numbers indicate the exons. Red exons show protein-coding regions while blue 
color represents untranslated regions. 
 
 
HNRNPA1 has three functional regions; two RNA-recognition motifs and one Glycine-rich Prion like domain. Numbers above the 
bars indicate amino acids harboring the domains. 
 
Description 
The HNRNPA1 gene is 6399 bases long and is on 
the plus strand. HNRNPA1 gene has 13 exons (Jean-
Philippe et al., 2013). 
Transcription 
HNRNPA1 produces two coding transcripts (Exon 
1-11). The difference between these coding 
transcripts is the presence or absence of exon 8 (only 
longer mRNA contains exon 8). A third one was 
reported as a potential non-coding transcript 
(Mendell et al, 2004).  This non-coding RNA 
transcript has exons 12 and 13, and it does not 
contain exon 8. 
Pseudogene 
There are 75 pseudogenes of HNRNPA1 which are: 
HNRNPA1P1, HNRNPA1P10, HNRNPA1P11, 
HNRNPA1P12, HNRNPA1P13, HNRNPA1P14, 
HNRNPA1P15, HNRNPA1P16, HNRNPA1P17, 
HNRNPA1P18, HNRNPA1P19, HNRNPA1P2, 
HNRNPA1P20, HNRNPA1P21, HNRNPA1P22, 
HNRNPA1P23, HNRNPA1P24, HNRNPA1P25, 
HNRNPA1P26, HNRNPA1P27, HNRNPA1P28, 
HNRNPA1P29, HNRNPA1P3, HNRNPA1P30, 
HNRNPA1P31, HNRNPA1P32, HNRNPA1P33, 
HNRNPA1P35, HNRNPA1P36, HNRNPA1P37, 
HNRNPA1P38, HNRNPA1P39, HNRNPA1P4, 
HNRNPA1P40, HNRNPA1P42, HNRNPA1P43, 
HNRNPA1P44, HNRNPA1P45, HNRNPA1P46, 
HNRNPA1P47, HNRNPA1P48, HNRNPA1P49, 
HNRNPA1P5, HNRNPA1P50, HNRNPA1P51, 
HNRNPA1P52, HNRNPA1P53, HNRNPA1P54, 
HNRNPA1P55, HNRNPA1P56, HNRNPA1P58, 
HNRNPA1P59, HNRNPA1P6, HNRNPA1P60, 
HNRNPA1P61, HNRNPA1P62, HNRNPA1P63, 
HNRNPA1P64, HNRNPA1P65, HNRNPA1P66, 
HNRNPA1P67, HNRNPA1P68, HNRNPA1P69, 
HNRNPA1P7, HNRNPA1P70, HNRNPA1P71, 
HNRNPA1P72, HNRNPA1P74, HNRNPA1P75,  
HNRNPA1P76, HNRNPA1P77, HNRNPA1P8, 




HNRNPA1 gene encodes a 372 amino acid protein. 
The protein is a member of heterogeneous nuclear 
ribonucleoproteins (hnRNPs) and has an estimated  
molecular weight of 38-39 kDa (Jean-Philippe, Paz,  
Caputi, 2013). 
Description 
HNRNPA1 has two RNA recognition motifs; RRM1 
and RRM2.  
These domains are known for binding to single-
stranded RNAs (Dreyfuss, Swanson, Piñol-Roma, 
1988).  
HNRNPA1 also possesses a prion-like domain 
(PLD).  
This domain is reported in RNA binding proteins 
that have been associated with neurodegenerative 
disorders such as Amyotrophic Lateral Sclerosis 
(Kim et al., 2013).  
In addition, glycine-rich region mediates subcellular 
localization and protein-protein interactions (Han, 
Tang, Smith, 2010). 
Expression 
HNRNPA1 mRNA is expressed in all human tissues 
including brain, skin, lung, breast and kidney (The 
Human Protein Atlas, 2018). 
Localisation 
HNRNPA1 protein is mainly nuclear; however, 
under certain conditions the protein is also present in 
the cytosol (Roy et al., 2014).  
In fact, HNRNPA1 may shuttle between nucleus and 
cytoplasm along with mRNAs (Jønson et al., 2007). 
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Expression of HNRNPA1 in different types of tissues is shown (The Human Protein Atlas, 2018). 
 
Function 
HNRNPA1 has a very broad range of reported 
functions including transcriptional regulation, 
alternative splicing, mRNA transport, translation 
and miRNA processing. Most surprisingly, 
HNRNPA1 can interact with certain promoters and 
induce transcriptional repression or activation of 
target genes. VDR (Vitamin D receptor) (H. Chen, 
Hewison, Hu, Adams, 2003), FGG (γ-fibrinogen) 
(Xia, 2005) and TK1 (thymidine kinase) (Lau et al., 
2000) promoters are transcriptionally repressed 
while APOE promoter is activated by HNRNPA1 
(Campillos et al., 2003).  
HNRNPA1 has an important role in mRNA splicing. 
The protein modulates alternative splicing of various 
genes including INSR (Insulin Receptor) (Talukdar 
et al., 2011), BRCA1 (Breast Cancer 1) (Goina, 
Skoko,  Pagani, 2008), PKM (Pyruvate Kinase 
M1/2) (David, Chen, Assanah, Canoll,  Manley, 
2010) and its own HNRNPA1 mRNA (Hutchison, 
LeBel, Blanchette,  Chabot, 2002). mRNA splicing 
is modulated by HNRNPA1 by exon skipping and 
splice site repression (Jean-Philippe et al., 2013).  
HNRNPA1 contributes to telomere regulation by 
promoting telomerase activity via binding to 
telomeric sequences, potentially as an auxiliary 
factor for the telomerase enzyme (Zhang, Manche, 
Xu,  Krainer, 2006).  
HNRNPA1 has roles in mRNA transport between 
nucleus and cytoplasm. Although the exact 
mechanism is unknown, HNRNPA1 binds to 
poly(A) tailed mRNAs both in the nucleus and 
cytoplasm (Mili, Shu, Zhao,  Pinol-Roma, 2001), 
and possibly aid their transfer through nuclear pores 
(Piñol-Roma  Dreyfuss, 1992).  
Another function attributed to HNRNPA1 is during 
translation. HNRNPA1 binds to internal ribosomal 
entry sites (IRES) that initiates 5' cap-independent 
translation of certain cellular and viral mRNAs (such 
as, MYC), CSDE1 (Upstream of NRAS),  
CCND1 (Cyclin D1), VEGFA (Vascular Endothelial 
Growth Factor), FGF2 (Fibroblast Growth Factor), 
APAF1, and XIAP mRNAs (Cammas et al. 2007). 
In addition, the HIV-1 IRES is stimulated by 
hnRNPA1 (Martènez-Salas, Piñeiro,  Fernández, 
2012).  
In addition to mRNA processing  and transport , 
HNRNPA1 interacts directly and specifically with 
C-terminal region of NF-kB alpha inhibitory subunit 
via its RNA-binding domain (between residues 95 
and 207) resulting in the activation of nuclear factor 
k B (Hay, Kemp, Dargemont,  Hay, 2001).  
The exact mechanism of HNRNPA1 and NF-kB 
interaction is not completely understood. However, 
in cells lacking HNRNPA1, activation of NF-kB is 
defected. When HNRNPA1 loss is rescued, an 
effective NF-kB response to signal induction is 
observed only upon ligand induction.  
As for the microRNA processing, HNRNPA1 binds 
to the terminal loop of pri-miR-18a, and facilitates 
MIR18A production by creating favorable cleavage 
site for DROSHA (Guil  Cáceres, 2007). In contrast, 
HNRNPA1 negatively affects MIRNLET7A1 (let-
7a) biogenesis. HNRNPA1 binds to terminal loop of 
pri-let-7a-1 and interferes with the binding of 
KHSRP (component of both Drosha and Dicer 
complexes, known to promote let-7a biogenesis); 
hence, inhibiting processing of pri-let-7a by Drosha 
(Michlewski  Cáceres, 2010). 
Homology 
HNRNPA1 gene has homologs across Amniota 
including P. troglodytes, M. mulatta, B. taurus, R. 
norvegicus, G. gallus, M. musculus and H. sapiens 
(NCBI HomoloGene, 2018).  
There is also a well-studied HNRNPA1 homolog in 
D. melanogaster called Hrp36 (Singh  Lakhotia, 
2012).  
In total, there are 97 species including invertebrates 
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Up to 106 substitution mutations were reported in the 
HNRNPA1 gene in 42,067 cancer patients. 
Reported mutations are generally missense 
mutations (70 of 106). There are also 4 nonsense 
mutations, 30 synonymous substitutions and 2 
frameshift deletions (COSMIC database, 2018). One 
of the frameshift deletions found in cancer patients 
is discovered in the Sanger Institute Cancer Genome 
Project (study ID :COSU652) while the other is 
discovered in 619 incident colorectal cancer patients 
in the study conducted by Giannakis et al(2016).  
Yu et al. (2018) also reported a recessive frameshift 
mutation in HNRNPA1 leading to deregulation of 
cardiac transcription network and multiple signaling 
pathways, including Bone Morphogenetic Protein, 
Notch and Fibroblast growth factor signaling. 
Implicated in 
Top note 
HNRNPA1 has been implicated in diverse diseases. 
Amyotrophic Lateral Sclerosis (ALS) 
Note 
Immunohistochemistry and immunofluorescence 
results showed that HNRNPA1 protein was 
decreased in the nuclei of neurons and the significant 
loss of HNRNPA1 in motor neurons with 
concomitant cytoplasmic aggregation in ALS cases 
while HNRNPA1 was mainly located in nucleus of 
motor neurons in normal cases (Honda et al., 2015). 
Mutations in prion-like domain (PrLD), enriched in 
uncharged polar amino acids and glycine, promote 
excess incorporation of HNRNPA1 into stress 
granules and cause the formation of cytoplasmic 
inclusions in animal models (H. J. Kim et al., 2013b). 
Whole-exome sequencing conducted by Liu et 
al.(2016) showed a missense mutation in HNRNPA1 
in Flail-Arm ALS patients leading to cytoplasmic 




Invasive breast cancer cells (MDA-MB-231) express 
the CD44v6 variants, which are regulated by 
HNRNPA1. Downregulation of HNRNPA1 induces 
a significant change in the expression levels of CD44 
isoforms through alternative splicing. Silencing of 
HNRNPA1 significantly induced cell death and 
caused a decrease in cell invasion in the MDA-MB-
231 cells (Loh et al., 2015). HNRNPA1 silencing 
through siRNAs significantly lowers the cell 
proliferation in MDA-MB-231 cells (Otsuka, 
Yamamoto, Ochiya, 2018). 
Prognosis 
In basal-like breast cancer, Kaplan-Meier survival 
analysis showed that patients (309 samples) showing 
high HNRNPA1 expression, had an distinctively  
shorter relapse-free survival than patients (309 
samples)  expressing low level of HNRNPA1 and 
that patients (121 samples) showing high HNRNPA1 
expression had a shorter overall survival than 
patients (120 samples) with low level of HNRNPA1 
expression. (Otsuka, Yamamoto, Ochiya, 2018). 
Cervical Carcinoma 
Note 
HNRNPA1 has higher expression in cervical 
carcinoma compared with normal tissue samples in 
32 patients with cervical cancer (Y. J. Kim et al., 
2017).  
HNRNPA1 expression is upregulated during 
differentiation of virus-infected epithelial cells in 
monolayer and 3D cell cultures. HNRNPA1 
interacts directly with the Human papillomavirus 
type 16 (HPV16) late regulatory element (LRE) 
(which has an important role in temporally 
controlling virus late gene expression during 
epithelial differentiation) in the nucleus of 
differentiated W12 cells in vitro and may facilitate 
the alternative splicing of late transcripts of virus  in 
differentiated epithelial cells (Cheunim, Zhang, 
Milligan, McPhillips,  Graham, 2008). 
Colon Cancer 
Note 
HNRNPA1 mRNA is overexpressed in 40-78% of 
colon cancer stages, compared with normal colon 
(Ubagai, Fukuda,  Tsuchiya, 2005).  
A cell line based study showed HNRNPA1 to be 
suppressed by MIR18a in SW620 cells through 
autophagolysosomal degradation and thus, 
HNRNPA1 silencing resulted in the suppression of 
colon cancer cell progression (Fujiya et al., 2014). 
Gastric Cancer (GC) 
Note 
GC tissues have elevated levels of HNRNPA1 
protein compared with normal tissues. HNRNPA1 
silencing significantly prevented anchorage-
dependent growth in GC cells and HNRNPA1 was 
important to cell growth and progression of GC. 
HNRNPA1 knockdown caused reduction in cell 
growth, invasion, migration and reversal of EMT 
(Epithelial to Mesenchymal Transition) in GC cells. 
Collectively, these results pointed out that 
HNRNPA1 may have a pivotal role in GC cell  
invasion and metastasis (Chen et al., 2018). 
Hepatocellular Carcinoma (HCC) 
Note 
High expression of HNRNPA1 was reported in the 
highly metastatic HCC cell lines and in tumor tissues 
of patients with recurrent HCC. HNRNPA1 
silencing reduced cell invasion in highly metastatic 
HCC cells while overexpression of HNRNPA1 
caused a significant increase in invasive behavior of 
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poorly metastatic HCC cells HNRNPA1 was 
reported to regulate the invasive capacity of HCC 
cells through regulating the CD44v6 
expression(Zhou et al., 2013). 
Lung Cancer 
Note 
The HNRNPA1 protein expression was reported to 
be upregulated in most tissue samples from lung 
cancer patients by immunohistochemistry 
(Boukakis, Patrinou-Georgoula, Lekarakou, 
Valavanis, Guialis, 2010). HNRNPA1 knockdown 
inhibited cell viability and colony formation of lung 
cancer cells and arrested cells in the G0/G1 phase 
(Liu, Zhou, Lou,  Zhong, 2016). 
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